title: Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB.
abstract: OBJECTIVE
  Clinically meaningful overactive bladder syndrome (OAB) symptom relief is associated with patient satisfaction. This study evaluated the effects of onabotulinumtoxinA on patient satisfaction and goal attainment.
  
  
  METHODS
  In a 36-week, multicenter, double-blind study, 313 participants with idiopathic OAB and urinary urgency incontinence inadequately managed with anticholinergics were randomized to placebo or one of five onabotulinumtoxinA doses. Assessment included a modified OAB-Patient Satisfaction with Treatment Questionnaire (PSTQ) and four Patient Global Assessment questions assessed changes in symptoms, quality of life, activity limitations, and emotions.
  
  
  RESULTS
  Mean changes from baseline in OAB-PSTQ scores for the main module (Q2-Q13) at week 12 were greater for each onabotulinumtoxinA group (range, -31.5% to -48.9%) versus placebo (-17.6%). Greater proportions of patients in onabotulinumtoxinA groups attained their primary goal (range, 34.5% to 65.3%) versus placebo (23.7%).
  
  
  CONCLUSIONS
  Patients with OAB are more likely to be satisfied and/or achieve their primary treatment goal with onabotulinumtoxinA treatment than with placebo, consistent with symptom improvements.
authors.affiliation: Department of Obstetrics and Gynecology, Stritch School of Medicine, Loyola University Chicago, 2160 S. First Avenue, Chicago, IL 60153, USA. Lbrubaker@lumc.edu
authors.forename: Linda
authors.initials: L
authors.lastname: Brubaker
authors.forename: Angelo
authors.initials: A
authors.lastname: Gousse
authors.forename: Peter
authors.initials: P
authors.lastname: Sand
authors.forename: Catherine
authors.initials: C
authors.lastname: Thompson
authors.forename: Vaishali
authors.initials: V
authors.lastname: Patel
authors.forename: Jihao
authors.initials: J
authors.lastname: Zhou
authors.forename: Brenda
authors.initials: B
authors.lastname: Jenkins
authors.forename: Karl-Dietrich
authors.initials: KD
authors.lastname: Sievert
mesh_terms: D000203:Activities of Daily Living; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011788:Quality of Life / Q000523:psychology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000150:complications*; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000209:etiology* / Q000523:psychology
chemical_list: D019274:Botulinum Toxins, Type A